Resistant arterial hypertension (RAH) is defined, according to the American Heart Association Scientific Position of 2018, as well as observed in the I Brazilian Position of RAH in 2012, when an individual’s blood pressure (BP) remains elevated above the blood pressure target, in spite of the use of three antihypertensive drugs of different therapeutic classes, commonly a long-acting dihydropyridine slow-calcium-channel antagonist drug; a renin-angiotensin-aldosterone system (RAAS) blocker, which may be an angiotensin II converting-enzyme inhibitor or angiotensin II AT1 receptor […]